Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pediatric study of CSL 2009 H1N1 influenza vaccine
2015-000176-10Phase 2
- Sponsor
- CSL Limited
- Start
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of CSL H1N1 Pandemic Influenza Vaccine in influenza (3 arms), sponsored by CSL Limited. Primary endpoint: Seroconversion rate 21 days after first study vaccination.
02
Drugs
CSL H1N1 Pandemic Influenza Vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2015-000176-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000176-10.